clinical trial · NCT06686576
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Qilu Pharmaceutical Co., Ltd.·phase3·recruiting·n = 363
Colon CancerQL1706CAPEOX/Capecitabine
brief summary
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
started
Dec 12, 2024
primary completion
Dec 1, 2030
completion
Dec 1, 2030
last updated
Dec 18, 2025
official title
A Phase Ib/III, Open-Label, Randomized Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol